MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino acid peptide encoded not by nuclear DNA but by the mitochondrial genome — making it part of a newly identified class of mitochondrial-derived peptides (MDPs). It was identified in 2015 by Lee et al. at the USC Davis School of Gerontology and has since emerged as a significant area of longevity and metabolic research.
MOTS-c activates AMPK (AMP-activated protein kinase), the master energy sensing enzyme that promotes fat oxidation, inhibits fat synthesis, increases mitochondrial biogenesis, and enhances insulin sensitivity. MOTS-c also upregulates GLUT4 expression and translocation to the cell membrane in muscle tissue, directly improving glucose uptake independently of insulin.
One of the most striking findings in MOTS-c research is its ability to mimic aspects of exercise adaptation at the cellular level. Studies in obese and aged mice showed that MOTS-c administration increased running capacity, reduced adipose tissue, and restored metabolic flexibility — the ability to switch between fat and glucose oxidation — to levels seen in young, healthy controls. These effects occurred without caloric restriction or increased physical activity.
In diet-induced obese mouse models, MOTS-c significantly improved insulin sensitivity, reduced fasting glucose, and decreased hepatic lipid accumulation. The mechanism appears to involve both direct AMPK activation in peripheral tissues and central nervous system effects that reduce hepatic glucose production.
MOTS-c levels decline with age in humans — circulating levels are significantly lower in elderly individuals compared to young adults. This age-dependent decline has led researchers to investigate MOTS-c as a longevity signal: the body's way of communicating mitochondrial stress and coordinating systemic metabolic adaptation. Exercise transiently increases circulating MOTS-c in humans, suggesting it may mediate some of exercise's systemic benefits.
Animal studies typically use 5–15 mg/kg subcutaneously. For research purposes, human-scale dosing protocols typically range from 5–30 mg subcutaneously, 2–3 times weekly. QSC supplies MOTS-c in 10 mg vials with Janoshik COA.
This page is for educational and research purposes only. All products sold by QSC are labelled for research use only and are not intended for human consumption. Nothing on this page constitutes medical advice.